Pfizer tracks experimental Drug's journey through the body
NCT ID NCT07127770
First seen Jan 09, 2026 · Last updated Jun 22, 2026 · Updated 30 times
Summary
This completed Phase 1 study in 9 healthy adult men aims to understand how the experimental drug PF-07104091 is absorbed, broken down, and removed from the body. Participants received a radioactive-labeled version of the drug by mouth and later by IV, with samples collected over 23 days. The results will help guide future dosing and development of this potential cancer treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY ADULTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ICON
Groningen, 9728 NZ, Netherlands
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PF-07104091 (a cyclin-dependent kinase-2 inhibitor)
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.